Skip to main content
PMC home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1976 Feb;3(1):185–191. doi: 10.1111/j.1365-2125.1976.tb00587.x

Plasma concentration of phenylbutazone and its therapeutic effect-studies in patients with rheumatoid arthritis.

M Orme, P J Holt, G R Hughes, C J Bulpitt, G H Draffan, S S Thorgeirsson, F Williams, D S Davies
PMCID: PMC1428814  PMID: 788739

Abstract

1 Phenylbutazone in doses of 50, 100, 200 and 300 mg/day has been given for four periods of 3 weeks to seven patients with rheumatoid arthritis. The trial was double-blind and the order of administration of doses was arranged to eliminate order and carry-over effects. 2 Before the trial and at the end of each period, the patient's responses were assessed by measurement of the duration of morning stiffness, the pain score, paracetamol tablet count, grip strength, digital joint size and articular index. 3 The plasma phenybutazone concentration was measured by gas-liquid chromatography and was also predicted by prior measurement of the phenazone half-life. 4. Compared with the pretreatment period, phenylbutazone had a significant therapeutic effect, as judged by morning stiffness, pain score and articular index, in a dose of 50 mg/day, but no statistically significant differences in effect were seen between the various doses of phenylbutazone. 5 There were no significant coorelations between the plasma concentration of phenylbutazone and any of the clinical assessments. 6 The plasma phenylbutazone concentration agreed closely with that predicted at doses of 50 and 100 mg, but at higher doses the plasma concentration was significantly lower than predicted (P less than 0.05). This may have been due to saturation of the protein binding sites at these doses.

Full text

PDF
189

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRODIE B. B., LOWMAN E. W., BURNS J. J., LEE P. R., CHENKIN T., GOLDMAN A., WEINER M., STEELE J. M. Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone. Am J Med. 1954 Feb;16(2):181–190. doi: 10.1016/0002-9343(54)90333-2. [DOI] [PubMed] [Google Scholar]
  2. BRUCK E., FEARNLEY M. E., MEANOCK I., PATLEY H. Phenylbutazone therapy; relation between the toxic and therapeutic effects and the blood level. Lancet. 1954 Jan 30;266(6805):225–228. doi: 10.1016/s0140-6736(54)90874-0. [DOI] [PubMed] [Google Scholar]
  3. BURNS J. J., ROSE R. K., CHENKIN T., GOLDMAN A., SCHULERT A., BRODIE B. B. The physiological disposition of phenylbutazone (butazolidin) in man and a method for its estimation in biological material. J Pharmacol Exp Ther. 1953 Nov;109(3):346–357. [PubMed] [Google Scholar]
  4. Bakke O. M., Draffan G. H., Davies D. S. The metabolism of phenylbutazone in the rat. Xenobiotica. 1974 Apr;4(4):237–254. doi: 10.3109/00498257409062542. [DOI] [PubMed] [Google Scholar]
  5. Boardman P. L., Hart F. D. Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis. Br Med J. 1967 Nov 4;4(5574):264–268. doi: 10.1136/bmj.4.5574.264. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Davies D. S., Thorgeirsson S. S. Individual differences in the plasma half-lives of lipid soluble drugs in man. Acta Pharmacol Toxicol (Copenh) 1971;29 (Suppl 3):181–190. doi: 10.1111/j.1600-0773.1971.tb03298.x. [DOI] [PubMed] [Google Scholar]
  7. Deodhar S. D., Dick W. C., Hodgkinson R., Buchanan W. W. Measurement of clinical response to anti-inflammatory drug therapy in rheumatoid arthritis. Q J Med. 1973 Apr;42(166):387–401. [PubMed] [Google Scholar]
  8. Eyberg C., Moodley G. P., Buchanan N. The pharmacology of malnutrition. Part I. Salicylate binding studies using normal serum/plasma and kwashiorkor serum. S Afr Med J. 1974 Dec 14;48(61):2564–2567. [PubMed] [Google Scholar]
  9. Mills J. A. Nonsteroidal anti-inflammatory drugs (first of two parts). N Engl J Med. 1974 Apr 4;290(14):781–784. doi: 10.1056/NEJM197404042901406. [DOI] [PubMed] [Google Scholar]
  10. Oka M., Rekonen A., Ruotsi A., Kuikka J. Measurement of systemic inflammatory activity in rheumatoid arthritis by the 99mTc method. Scand J Rheumatol. 1973;2(3):101–107. doi: 10.3109/03009747309098826. [DOI] [PubMed] [Google Scholar]
  11. Ritchie D. M., Boyle J. A., McInnes J. M., Jasani M. K., Dalakos T. G., Grieveson P., Buchanan W. W. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. Q J Med. 1968 Jul;37(147):393–406. [PubMed] [Google Scholar]
  12. Vesell E. S., Page J. G. Genetic control of drug levels in man: phenylbutazone. Science. 1968 Mar 29;159(3822):1479–1480. doi: 10.1126/science.159.3822.1479. [DOI] [PubMed] [Google Scholar]
  13. Wagner J. G., Northam J. I., Alway C. D., Carpenter O. S. Blood levels of drug at the equilibrium state after multiple dosing. Nature. 1965 Sep 18;207(5003):1301–1302. doi: 10.1038/2071301a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES